合作目标是测试在临床试验中的区块链技术是否提供了一个分散的框架，以保证数据完整性、来源、透明度和患者赋权以及过程自动化，最终以降低成本提高试验质量和患者安全性。
Boehringer Ingelheim Ltd. and IBM Canada announced today at the Healthcare Information and Management Systems Society conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials.
勃林格殷格翰（Boehringer Ingelheim）Ltd .和 IBM Canada 今天在弗洛里达州奥兰多召开的医疗信息和管理系统协会会议上宣布，他们计划在临床试验中探索使用区块链技术。
This collaboration underscores Boehringer Ingelheim's commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada.
这种合作强调了勃林格殷格翰（Boehringer Ingelheim）对医疗创新的承诺，并标志着区块链技术将首次在加拿大的临床试验环境中得到探索。
Based on the findings of regulatory authorities, processes to ensure the quality of clinical trials are frequently inadequate, and clinical trial records are often erroneous or incomplete, which may put patient safety and interpretability of trials at risk.
根据监管部门的调查结果，确保临床试验质量的过程经常不充分，临床试验记录往往错误或不完整，可能使患者的安全性和试验的可解释性受到威胁。
Significant opportunity exists to improve the quality of clinical trial processes and record keeping. Boehringer Ingelheim (Canada) Ltd. and IBM Canada aim to test whether blockchain technology in clinical trials provides a decentralized framework that enables data integrity, provenance, transparency, and patient empowerment as well as automation of processes, ultimately improving trial quality and patient safety at reduced cost.
提高临床试验过程质量和记录保存的重要机会。勃林格殷格翰（Boehringer Ingelheim）（加拿大）有限公司和 IBM 加拿大公司的目标是测试在临床试验中的区块链技术是否提供了一个分散的框架，使数据完整性、来源、透明度和患者赋权以及过程自动化，最终以降低成本提高试验质量和患者安全性。
"Our guiding philosophy is to bring value to patients and the healthcare system through innovation," said Dr. Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. "The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment. Patients are at the heart of everything we do, so we are looking into novel solutions to improve patient safety and empowerment."
勃林格殷格翰（Boehringer Ingelheim）（加拿大）有限公司医疗和监管事务副总裁 Uli Br ö dl 博士说：“我们的指导思想是通过创新为患者和医疗系统带来价值。临床试验生态系统非常复杂，涉及不同的利益相关者，因此信任有限。没有真正的病人授权，透明度和过程效率低下。病人是我们所做一切的核心，因此我们正在寻找新的解决方案，以改善病人的安全和增强能力。”
IBM Canada brings core blockchain technologies to this collaboration which provides patient consent, secure health data exchange and patient engagement. IBM's technology helps provide trust and transparency around the complex trial process.
IBMCanada 为这种协作提供了核心区块链技术，它提供了患者同意、安全的健康数据交换和患者参与。IBM 的技术有助于在复杂的测试过程中提供信任和透明度。
閱讀更多 匯眾醫療 的文章
